Cardiovascular manifestations in patients infected with the human immunodeficiency virus

Arquivos Brasileiros de Cardiologia

Volumn 85, Issue 5, 2005, Pages

  Abrahão Hajjar, Ludhmila ^a   Calderaro, Daniela ^a   Pai, Ching Yu ^a   Giuliano, Isabela ^a   De Oliveira Lima, Enéas Martins ^a   Barbaro, Giuseppe ^a   Caramelli, Bruno ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLESTYRAMINE; COTRIMOXAZOLE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; FIBRIC ACID DERIVATIVE; FOSCARNET; GANCICLOVIR; GEMFIBROZIL; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METFORMIN; METICILLIN; NICOTINIC ACID; PENTAMIDINE; PROSTACYCLIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNINDEXED DRUG; VASODILATOR AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ATHEROGENESIS; ATHEROSCLEROSIS; BACTERIAL ENDOCARDITIS; BLOOD VESSEL INJURY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENDOCARDIAL DISEASE; FLUSHING; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPID METABOLISM; LIPODYSTROPHY; LIVER TOXICITY; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; MYOCARDIAL DISEASE; MYOCARDITIS; NONHUMAN; OBESITY; PERICARDIAL DISEASE; PERICARDIAL EFFUSION; PREVALENCE; PRURITUS; PULMONARY HYPERTENSION; RESTENOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; TOXICITY; UNSPECIFIED SIDE EFFECT; VIROLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATHEROSCLEROSIS; CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; HIV INFECTIONS; HUMANS; HYPERTENSION, PULMONARY; RISK FACTORS;

EID: 31144441192     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Yunis NA, Stone VE. Cardiac manifestations of HIV/AIDS: A review of disease spectrum and clinical management. J AIDS Hum Retrovirol 1998; 18: 145-54.
2. Barbaro G. Pathogenesis of HIV-associated heart disease. AIDS 2003; 17: S12-S20.
3. Prendergast BD. HIV and cardiovascular medicine. Heart 2003; 89 (7): 793-800.
4. Barbaro G. Cardiovascular manifestations of HIV infection. J R Soc Med 2001; 94: 384-0.
5. Autran BR, Gorin I, Leibowitch M et al. AIDS in a Haitian woman with cardiac Kaposi's sarcoma and Whipple's disease. Lancet 1983; I: 767-8.
6. D'Amati G, Di Gioia CR, Gallo P. Pathological findings of HIV-associated cardiovascular disease. Ann N Y Acad Sci 2001; 946; 23-45.
7. Barbaro G, Di Lorenzo G, Grisorio B et al. Cardiac involvement in the acquired immunodeficiency syndrome. A multicenter clinicalpathological study. AIDS Res Hum Retroviruses 1998; 14:1071-7.
8. Arshad A, Bansal A, Patel RC. Cardiac complications of human immunodeficiency virus infection: diagnostic and therapeutic considerations. Heart Disease 2000; 2; 133-45.
9. Barbaro G. Cardiovascular manifestations of HIV infection. Circulation 2002; 106: 1420-5.
10. Barbaro G, Fisher SD, Pellicelli AM et al. The expanding role of the cardiologist in the care of HIV infected patients. Heart 2001; 86: 365-73.
11. Rerkpattanapipat P, Wongpraparut N, Jacobs LE et al. Cardiac manifestations of acquired immunodeficiency syndrome. Arch Intern Med 2000; 160: 602-8.
12. Milei J, Grana D, Fernández Alonso G et al. Cardiac involvement in acquired immunodeficiency syndrome - a review to push action. Clin Cardiol 1998; 21: 465-72.
13. Heidenreich PA, Eisenberg MJ, Kee LL et al. Pericardial effusion in AIDS: incidence and survival. Circulation 1995; 92: 3229-34.
14. Silva-Cardoso J, Moura B, Martins L et al. Pericardial involvement in human immunodeficiency virus infection. Chest 1999; 115: 418-22.
15. Chen Y, Brennessel D, Walters J et al. Human immunodeficiency virus-associated pericardial effusion: report of 40 cases and review of the literature. Am Heart J 1999; 137: 516-21.
16. Miller RF, Howling SJ, Reid AJ et al. Pleural effusions in patients with AIDS. Sex Trans Infect 2000; 76: 122-5.
17. Dal Maso L, Serraino D, Franceschi S. Epidemiology of HIVassociated malignancies. Cancer Treat Res 2001; 104: 1-18.
18. Duong M, Duboi C, Buisson M et al. Non-Hodgkin's Iymphoma of the heart in patients infected with human immunodeficiency virus. Clin Cardiol 1997; 20: 497-2.
19. Gowda RM, Khan IA, Mehta NJ, Gowda MR, Sacchi TJ. Cardiac Tamponade in patients with immunodeficiency virus disease. Angiology 2003; 54 (4): 469-74.
20. Estok L, Wallach F. Cardiac tamponade in a patient with AIDS: a review of pericardial disease in patients with HIV infection. Mt Sinai J Med 1998; 65: 33-9.
21. Sanna P, Bertoni F, Zucca E et al. Cardiac involvement in HIV- related non Hodgkin lymphoma: a case report and short and short review of the literature. Ann Hematol 1998; 77: 75-8.
22. Currie PF, Sutherland GR, Jacob AJ et al. A review of endocarditis in acquired immunodeficiency syndrome and human immunodeficiency syndrome. Eur Heart J 1995; 16 (suppl B): 15-18.
23. Nahass RG, Weinstein MP, Bartels J et al. Infective endocarditis in intravenous drug users: a comparison of human immunodeficiency virus type 1-negative and-positive patients. J Infect Dis 1990; 162: 967-0.
24. Moss R, Munt B. Injection drug use and right sided endocarditis. Heart 2003; 89: 577-81.
25. Barbaro G, Fisher SD, Lipshultz SE. Pathogenesis of HIV-associated cardiovascular complications. Lancet Infect Dis 2001; 1: 115-124.
26. Barbaro G, Klatt EC. HIV infection and the cardiovascular system. AIDS Rev 2002; 4: 93-103.
27. Lipshultz SE. Dilated cardiomiopathy in HIV-infected patients. N Eng J Med 1998; 339: 1153-55.
28. Levy WS, Simon GL, Rios JC, Ross AM. Prevalence of cardiac abnormalities in human immunodeficiency virus infection. Am J Cardiol 1989; 63: 86-9.
29. Barbaro G, Di Lorenzo G, Grisorio B et al. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIVpositive patients. N Engl J Med 1998; 339:1093-9.
30. Barbaro G, Barbarini G, Di Lorenzo G. Early impairment of systolic and diastolic function in asymptomatic HIV-positive patients: a multicenter echocardiographic and echo-Doppler study. Aids Res and Hum Retroviruses 1996; 12 (16): 1559-63.
31. Corallo S, Mutinelli MR, Moroni M et al. Echocardiography detects myocardial damage in AIDS: Prospective study in 102 patients. Eur Heart J 1988; 9: 887-2.
32. Barbaro G. Dilated cardiomyopathy in the acquired immunodeficiency syndrome. Eur Heart J 1999; 20: 629-30.
33. Lipshultz SE, Easley KA, Orav EJ et al. Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation 1998; 97 (13): 1246-56.
34. Fantoni M, Autore C, Del Borgo C. Drugs and cardiotoxicity in HIV and AIDS. Ann N Y Acad Sci 2001; 946: 179-99.
35. Lewis W. Cardiomyopathy in AIDS: a pathophysiological perspective. Prog Cardiovasc Dis 2000; 43: 151-70.
36. Currie PF, Goldman JH, Caforio AL et al. Cardiac autoimmunity in HIV related heart muscle disease. Heart 1998; 79: 599-604.
37. Grody W, Cheng L, Lewis W. Infection of the heart by the human immunodeficiency virus. Am J Cardiol 1990; 66: 203-6.
38. Herskowitz A, Willoughby SB, Baughman KL et al. Cardiomyopathy associated with anti-retroviral therapy in patients with HIV infection: a report of six cases. Ann Intern Med 1992; 116: 311-3.
39. Hoffman M, Lipshultz SE, Miller TL. Malnutrition and cardiac abnormalities in the HIV-infected patients. In: Miller TL, Gorbach S, eds. Nutritional Aspects of HIV Infection. London, UK: Arnold, 1999, 33-9.
40. Lewis W, Gupp IL, Grupp G et al. Cardiac dysfunction in the HIV-1 transgenic mouse treated with zidovudine. Lab Invest 2000; 80: 187-7.
41. Barbaro G, Di Lorenzo G, Soldini M et al. The intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus associated cardiomyopathy. Circulation 1999; 100: 633-9.
42. Chi D, Henry J, Kelley J et al. The effects of HIV infection on endothelial function. Endothelium 2000; 7: 223-42.
43. Barbaro G, Di Lorenzo G, Soldini M et al. Clinical course of cardiomyopathy in HIV-infected patients with or without encephalopathy related to the myocardial expression of TNF-a and iNOS. AIDS 2000; 14: 827-8.
44. Miller TL, Orav EJ, Colan SD, Lipshultz SE. Nutritional status and cardiac mass and function in children infected with the human immunodeficiency virus. Am J Clin Nutr 1997; 66 (3): 660-4.
45. Lipshultz SE, Orav EJ, Sanders SP et al. Immunoglobulins and left ventricular structure and function in pediatric HIV infection. Circulation 1995; 92: 2220-5.
46. Golpe R, Fernandez-Infante B, Fernandez Rozas S. Primary pulmonary hypertension associated with human immunodeficiency virus infection. Postgrad Med J 1998; 74: 400-4.
47. Pellicelli AM, Palmieri F, D'Ambrosio C et al. Role of human immunodeficiency virus primary pulmonary hypertension: case reports. Angiology 1998; 49: 1005-1.
48. Pellicelli A, Barbaro G, Palmieri F et al. Primary pulmonary hypertension in HIV disease: a systematic review. Angiology 2001; 52: 31-41.
49. Mehta NJ, Khan IA, Mehta RN et al. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 2000; 118: 1133-41.
50. Mesa RA, Edell ES, Dunn WF et al. Human immunodeficiency virus infection and pulmonary hypertension. Mayo Clin Proc 1998; 73: 37-44.
51. Opravil M, Pechere M, Speich R et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care 1997; 155: 990-5.
52. Sposito A, Caramelli B, Sartori AM Ramires JAF. The Lipoprotein Profile in HIV Infected Patients. Braz J Infect Dis 1997: 275-83.
53. Constans J, Pellegrin JL, Peuchant E et al. Plasma lipids in HIVinfected patients: a prospective study in 95 patients. Eur J Clin Invest 1994; 24: 416-20.
54. Carr A, Samaras K, Chisholm DJ, Cooper D. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodistrophy, hyperlipidaemia, and insulin resistance. The Lancet 1998; 351: 1881-83.
55. Paton P, Tabib A, Loire R, Tete R. Coronary artery lesions and human immunodeficiency virus infection. Res Virol 1993; 144 (3): 225-31.
56. Barbaro G, Barbarini G, Pellicelli A. HIV-Associated Coronary Arteritis in a Patient with Fatal Myocardial Infarction. N Engl J Med 2001; 344: 1799.
57. Rickerts V, Brodt H, Staszewski S, Stille W. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res 2000; 5 (8): 329-33.
58. Holmberg S, Moorman A, Williamson J et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1.The Lancet 2002; 360: 1747-8.
59. Klein D, Hurley LB, Quesenberry Jr CP, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection ? J AIDS 2002; 30: 471-7.
60. David M, Hornung R, Fichtenbaum CJ. Ischemic Cardiovascular Disease in Persons with Human Immunodeficiency Virus Infection. CID 2002; 34: 98-102.
61. Bozzette S, Ake C, Tam H, Chang S et al. Cardiovascular and Cerebrovascular Events in Patients Treated for Human Immunodeficiency Virus Infection. N Engl J Med 2003; 348: 702-10.
62. Currier J, Taylor A, Boyd F et al. Coronary Heart Disease in HIVInfected Individuals. J AIDS 2003; 33: 506-12.
63. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. N Engl J Med 2003; 349: 1993-2003.
64. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90: 583-612.
65. Varriale P, Saravi G, Hernandez E, Carbon F. Acute myocardial infarction in patients infected with human immunodeficiency virus. Am Heart J 2004; 147: 55-9.
66. Matetzky S, Domingo M, Kar S et al. Acute Myocardial Infarction in Human Immunodeficiency Virus-Infected Patients. Arch Intern Med 2003; 163: 457-60.
67. Hsue P, Giri K, Erickson S et al. Clinical Features of Acute Coronary Syndromes in Patients With Human Immunodeficiency Virus Infection. Circulation 2004; 109: 316-19.
68. Morrow DA, Antman EM, Charlesworth A et al. TIMI risk score for STelevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation. Circulation 2000; 102: 2031-7.
69. Antman EM, Cohen M, Bernink PJLM et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000; 284: 835-42.
70. Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjets. Eur J Clin Microbiol Infect Dis 2004; 23: 625-30.
71. Depairon M, Chessex S, Sudre P et al. Premature atherosclerosis in HIV-infected individuals-focus on protease inhibitor therapy. AIDS 2001; 15: 329-34.
72. Hsue P, Lo JC, Franklin A et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109: 1603-8.
73. III Diretrizes Brasileiras sobre Dislipidemia e Diretriz de Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia Arq Bras Cardiol 2001; 77(supl. III).
74. Dube MP, Stein JH, Aberg JA et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus infected adults receiving antiretroviral therapy. Clin Infec Dis 2003; 37: 613-27.
75. Henry K, Melroe H, Huebsch J et al. Severe premature coronary artery disease with protease inhibitors. The Lancet 1998; 351: 1328.
76. Périard D, Telenti A, Sudre P et al. Atherogenic dyslipidaemia in HIVinfected individuals treated with protease inhibitors. Circulation 1999; 100: 700-5.
77. Kannel WB, Giordano M. Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia. Am J Cardiol 2004; 94: 901-6.
78. DATASUS. Estatísticas vitais. In: Ministério da Saúde; 2004.
79. Selik RM, Lindegren ML. Changes in deaths reported with human immunodeficiency virus infection among United States children less than thirteen years old, 1987 through 1999. Pediatr Infect Dis J 2003; 22(7): 635-41.
80. Guyer B, MacDorman MF, Martin JA, Peters KD, Strobino DM. Annual summary of vital statistics-1997. Pediatrics 1998; 102 (6): 1333-49.
81. Kearney DL, Perez-Atayde AR, Easley KA et al. Postmortem cardiomegaly and echocardiographic measurements of left ventricular size and function in children infected with the human immunodeficiency virus. The Prospective P2C2 HIV Multicenter Study. Cardiovasc Pathol 2003; 12 (3):140-8.
82. Lipshultz SE, Easley KA, Orav EJ et al. Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 2000; 343 (11): 759-66.
83. Starc TJ, Lipshultz SE, Kaplan S et al. Cardiac complications in children with human immunodeficiency virus infection. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group, National Heart, Lung, and Blood Institute. Pediatrics 1999; 104(2): 14.
84. Keesler MJ, Fisher SD, Lipshultz SE. Cardiac manifestations of HIV infection in infants and children. Ann N Y Acad Sci 2001; 946: 169-78.
85. Langston C, Cooper ER, Goldfarb J et al. Human immunodeficiency virus-related mortality in infants and children: data from the pediatric pulmonary and cardiovascular complications of vertically transmitted HIV (P(2)C(2)) Study. Pediatrics 2001; 107 (2): 328-38.
86. Fisher SD, Lipshultz SE. Epidemiology of cardiovascular involvement in HIV disease and AIDS. Ann N Y Acad Sci 2001; 946: 13-22.
87. Velasquez EM, Glancy DL. Cardiovascular disease in patients infected with the human immunodeficiency virus. J La State Med Soc 2003; 155 (6): 314-24.
88. Herdy GV, Ramos R, Bazin AR et al. Correlação histopatológica em 50 casos de Síndrome de Imunodeficiência Adquirida. Um estudo retrospectivo. Arq Bras Cardiol 1994; 62 (2): 95-8.
89. Shearer WT, Lipshultz SE, Easley KA et al. Alterations in cardiac and pulmonary function in pediatric rapid human immunodeficiency virus type 1 disease progressors. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted Human Immunodeficiency Virus Study Group. Pediatrics 2000; 105 (1): 9.
90. Nogueira G, Macedo AJ, Paixao A et al. Morbidade cardiovascular em crianças com infecção pelo vírus da Imunodeficiência Humana. Acta Med Port 1998; 11 (12): 1051-7.
91. Bannerman C, Chitsike I. Cor pulmonale in children with human immunodeficiency virus infection. Ann Trop Paediatr 1995; 15 (2): 129-34.
92. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest 2000; 118 (4): 1133-41.
93. Lipshultz SE, Orav EJ, Sanders SP, Colan SD. Immunoglobulins and left ventricular structure and function in pediatric HIV infection. Circulation 1995; 92 (8): 2220-5.
94. Lai WW, Colan SD, Easley KA et al. Dilation of the aortic root in children infected with human immunodeficiency virus type 1: The Prospective P2C2 HIV Multicenter Study. Am Heart J 2001; 141 (4): 661-70.
95. Bowles NE, Kearney DL, Ni J et al. The detection of viral genomes by polymerase chain reaction in the myocardium of pediatric patients with advanced HIV disease. J Am Coll Cardiol 1999; 34 (3): 857-65.
96. Domanski MJ, Sloas MM, Follmann DA et al. Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. J Pediatr 1995; 127 (1): 137-46.
97. Herdy GV, Pinto CA, Lopes VG et al. Study of the cardiac alterations in HIV-infected children consequent to the antiretroviral therapy. Prospective study of 47 cases. Arq Bras Cardiol 2003; 80 (3): 311-20.
98. Bezold LI, Bricker JT. Acquired heart disease in children. Curr Opin Cardiol 1994; 9 (1): 121-9.
99. Cossarizza A, Troiano L, Mussini C. Mitochondria and HIV infection: the first decade. J Biol Regul Homeost Agents 2002; 16 (1): 18-24.
100. de Larranaga GF, Petroni A, Deluchi G, Alonso BS, Benetucci JA. Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients. Blood Coagul Fibrinolysis 2003; 14 (1): 15-8.
101. Matzen K, Dirkx AE, Oude Egbrink MG et al. HIV-1 Tat increases the adhesion of monocytes and T-cells to the endothelium in vitro and in vivo: implications for AIDS-associated vasculopathy. Virus Res 2004; 104 (2): 145-55.
102. Bonnet D, Aggoun Y, Szezepanski I, Bellal N, Blanche S. Arterial stiffness and endothelial dysfunction in HIV-infected children. Aids 2004; 18 (7): 1037-41.
103. Cheseaux JJ, Jotterand V, Aebi C et al. Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. J Acquir Immune Defic Syndr 2002; 30 (3): 288-93.
104. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185 (4): 456-62.